Agalsidase alfa for the treatment of Fabry disease: New data on clinical efficacy and safety

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 255-261

  Beck, Michael ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

galactosidase A; Agalsidase alfa; Enzyme replacement therapy; Fabry disease; Lysosomal storage disorder

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANTIHISTAMINIC AGENT; CORTICOSTEROID; PLACEBO; ALPHA GALACTOSIDASE; ISOENZYME;

CELL LINE; CHILL; CHO CELL; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FABRY DISEASE; FLUSHING; HEARING; HEART SIZE; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY FUNCTION; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SWEATING; THORAX PAIN; TREATMENT OUTCOME; ANIMAL; FEMALE; HAMSTER; MALE;

CRICETULUS GRISEUS;

ALPHA-GALACTOSIDASE; ANIMALS; CRICETINAE; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE; TREATMENT OUTCOME;

EID: 66149092757     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802658428     Document Type: Review

References (40)

1. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-24 • The first comprehensive description of clinical manifestation in females with Fabry disease.
2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760 (Pubitemid 33032930)
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775 (Pubitemid 33032933)
4. Schäfer E, Baron K, Widmer U, et al. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 2005;25:412-418
5. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-156 (Pubitemid 29396979)
6. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-254 (Pubitemid 29058114)
7. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40 • First newborn screening for Fabry disease.
8. Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003;13:305-313 (Pubitemid 36592316)
9. Shin SH, Kluepfel-Stahl S, Cooney AM, et al. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics 2008;18:773-780
10. Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 2006;12:367-373 (Pubitemid 44149238)
11. Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with fabry disease. Proc Natl Acad Sci USA 2000;97:365-370 (Pubitemid 30055837)
12. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9 • First placebo-controlled clinical trial of agalsidase alfa.
13. Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21:345-354 (Pubitemid 43159987)
14. Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 2007;9:504-509 (Pubitemid 47282038)
15. Ries M, Clarke JT, Whybra C, et al. Enzyme replacement in fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J Clin Pharmacol 2007;47:1222-1230 (Pubitemid 47459666)
16. Baehner F, Kampmann C, Whybra C, et al. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherited Metab Dis 2003;26:617-27 • First clinical trial of agalsidase alfa in females.
17. Pastores GM, Boyd E, Crandall K, et al. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007;22:1920-1925 (Pubitemid 47244761)
18. Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-844 (Pubitemid 39657931)
19. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153-158 (Pubitemid 351211719)
20. Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children withFabry disease. Pediatrics 2006;118:924-932 (Pubitemid 46091613)
21. Schwarting A, Dehout F, Feriozzi S, et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006;66:77-84 (Pubitemid 44219432)
22. Vylet'al P, Hulkova H, Zivna M, et al. Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. J Inherit Metab Dis 2008;31:508-517
23. Hoffmann B, Garcia de Lorenzo A, Mehta A, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005;42:247-252 (Pubitemid 40380306)
24. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-710 (Pubitemid 37484832)
25. Hoffmann B, Reinhardt D, Koletzko B. Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease. Eur J Gastroenterol Hepatic 2004;16:1067-1069 (Pubitemid 39411129)
26. Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-794 (Pubitemid 38139379)
27. Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007;96:122-127 (Pubitemid 46307392)
28. Whybra C, Kampmann C, Miebach E, et al. Long-term efficacy and safety of agalsidase alfa in women with Fabry disease [abstract]. J Inherit Metab Dis 2008;31 (Suppl 1): 107
29. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307 (Pubitemid 38443553)
30. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008;94:319-325
31. Wendt S, Whybra C, Kampmann C, et al. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 2005;28:787-8 • First enzyme replacement therapy with agalsidase alfa in pregnancy.
32. Dehout F, Roland D, Henry F, et al. Successful pregnancy in a patient with Fabry disease receiving enzyme replacement therapy [abstract]. Acta Paediatr 2006;95 (Suppl 451): 137
33. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005;84:261-268 (Pubitemid 41368479)
34. Moore DF, Ye F, Brennan ML, et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 2004;20:674-683 (Pubitemid 39313744)
35. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006;20:1-26 (Pubitemid 41811224)
36. Gelderman MP, Schiffmann R, Simak J. Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler Thromb Vasc Biol 2007;27:e138-9 (Pubitemid 46986127)
37. Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007;18:1576-1583 (Pubitemid 46717525)
38. Whitfield PD, Calvin J, Hogg S, et al. Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J Inherit Metab Dis 2005;28:21-33 (Pubitemid 40253981)
39. Murray GJ, Anver MR, Kennedy MA, et al. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 2007;90:307-12 • Comprehensive analysis of tissue distribution of agalsidase alfa.
40. Cai SR, Xu G, Becker-Hapak M, et al. The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci 2006;27:311-319 (Pubitemid 43143256)